Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination

Vaccine

Volumn 29, Issue 11, 2011, Pages 2140-2148

  Vrtala, Susanne ^a   Fohr, Monika ^a   Campana, Raffaela ^a   Baumgartner, Christian ^b   Valent, Peter ^b   Valenta, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergy; Immunogenicity; Immunotherapy; Oligomerization

Indexed keywords

BET V 1 VACCINE; DNA; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; MONOMER; POLLEN ANTIGEN; UNCLASSIFIED DRUG;

ALLERGY VACCINATION; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MOLECULAR CLONING; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; VACCINATION;

ALLERGENS; ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGENS, PLANT; BETULA; CLONING, MOLECULAR; DESENSITIZATION, IMMUNOLOGIC; ESCHERICHIA COLI; FEMALE; GENETIC ENGINEERING; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; POLLEN; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL;

EID: 79951809149     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.080     Document Type: Article

References (49)

1. Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102(4 Pt 1):558-562.
2. Mellerup M.T., Hahn G.W., Poulsen L.K., Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000, 30(10):1423-1429.
3. Valenta R., Ferreira F., Focke-Tejkl M., Linhart B., Niederberger V., Swoboda I., et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010, 28:211-241.
4. Vrtala S., Focke-Tejkl M., Swoboda I., Kraft D., Valenta R. Strategies for converting allergens into hypoallergenic vaccine candidates. Methods 2004, 32(3):313-320.
5. Vrtala S., Hirtenlehner K., Vangelista L., Pastore A., Eichler H.G., Sperr W.R., et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997, 99(7):1673-1681.
6. van Hage-Hamsten M., Kronqvist M., Zetterstrom O., Johansson E., Niederberger V., Vrtala S., et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999, 104(5):969-977.
7. Pauli G., Purohit A., Oster J.P., De Blay F., Vrtala S., Niederberger V., et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 2000, 30(8):1076-1084.
8. Vrtala S., Akdis C.A., Budak F., Akdis M., Blaser K., Kraft D., et al. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 2000, 165(11):6653-6659.
9. van Hage-Hamsten M., Johansson E., Roquet A., Peterson C., Andersson M., Greiff L., et al. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Clin Exp Allergy 2002, 32(10):1448-1453.
10. Nopp A., Hallden G., Lundahl J., Johansson E., Vrtala S., Valenta R., et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. J Allergy Clin Immunol 2000, 106(1 Pt 1):101-109.
11. Mahler V., Vrtala S., Kuss O., Diepgen T.L., Suck R., Cromwell O., et al. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin Exp Allergy 2004, 34(1):115-122.
12. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004, 101(Suppl. 2):14677-14682.
13. Gafvelin G., Thunberg S., Kronqvist M., Gronlund H., Gronneberg R., Troye-Blomberg M., et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 2005, 138(1):59-66.
14. Reisinger J., Horak F., Pauli G., van Hage M., Cromwell O., Konig F., et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005, 116(2):347-354.
15. Purohit A., Niederberger V., Kronqvist M., Horak F., Gronneberg R., Suck R., et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008, 38(9):1514-1525.
16. Pree I., Shamji M.H., Kimber I., Valenta R., Durham S.R., Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010, 40(9):1346-1352.
17. Pree I., Reisinger J., Focke M., Vrtala S., Pauli G., van Hage M., et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 2007, 179(8):5309-5316.
18. Paul W.E., Siskind G.W., Benacerraf B. Studies on the effect of the carrier molecule on antihapten antibody synthesis. II. Carrier specificity of anti-2,4-dinitrophenyl-poly-l-lysine antibodies. J Exp Med 1966, 123(4):689-705.
19. Paul W.E., Katz D.H., Goidl E.A., Benacerraf B. Carrier function in anti-hapten immune responses. II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses. J Exp Med 1970, 132(2):283-299.
20. Edlmayr J., Niespodziana K., Linhart B., Focke-Tejkl M., Westritschnig K., Scheiblhofer S., et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009, 182(10):6298-6306.
21. Kundig T.M., Senti G., Schnetzler G., Wolf C., Prinz Vavricka B.M., Fulurija A., et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006, 117(6):1470-1476.
22. Tighe H., Takabayashi K., Schwartz D., Van Nest G., Tuck S., Eiden J.J., et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000, 106(1 Pt 1):124-134.
23. Focke M., Mahler V., Ball T., Sperr W.R., Majlesi Y., Valent P., et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001, 15(11):2042-2044.
24. Focke M., Linhart B., Hartl A., Wiedermann U., Sperr W.R., Valent P., et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 2004, 34(10):1525-1533.
25. Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010;40(3):385-97.
26. Linhart B., Jahn-Schmid B., Verdino P., Keller W., Ebner C., Kraft D., et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002, 16(10):1301-1303.
27. Linhart B., Hartl A., Jahn-Schmid B., Verdino P., Keller W., Krauth M.T., et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 2005, 115(5):1010-1016.
28. King T.P., Jim S.Y., Monsalve R.I., Kagey-Sobotka A., Lichtenstein L.M., Spangfort M.D. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 2001, 166(10):6057-6065.
29. Bonura A., Corinti S., Artale A., Di Felice G., Amoroso S., Melis M., et al. A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. Int Arch Allergy Immunol 2007, 142(4):274-284.
30. Linhart B., Mothes-Luksch N., Vrtala S., Kneidinger M., Valent P., Valenta R. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol Chem 2008, 389(7):925-933.
31. Vrtala S., Hirtenlehner K., Susani M., Akdis M., Kussebi F., Akdis C.A., et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001, 15(11):2045-2047.
32. Johansson J., Hellman L. Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine. Vaccine 2007, 25(9):1676-1682.
33. Valenta R., Duchene M., Vrtala S., Birkner T., Ebner C., Hirschwehr R., et al. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol 1991, 88(6):889-894.
34. Studier F.W., Rosenberg A.H., Dunn J.J., Dubendorff J.W. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol 1990, 185:60-89.
35. Hoffmann-Sommergruber K., Susani M., Ferreira F., Jertschin P., Ahorn H., Steiner R., et al. High-level expression and purification of the major birch pollen allergen, Bet v 1. Protein Expr Purif 1997, 9(1):33-39.
36. Vrtala S., Susani M., Sperr W.R., Valent P., Laffer S., Dolecek C., et al. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). J Allergy Clin Immunol 1996, 97(3):781-787.
37. Fling S.P., Gregerson D.S. Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. Anal Biochem 1986, 155(1):83-88.
38. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227(5259):680-685.
39. Gill S.C., von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 1989, 182(2):319-326.
40. Valenta R., Duchene M., Ebner C., Valent P., Sillaber C., Deviller P., et al. Profilins constitute a novel family of functional plant pan-allergens. J Exp Med 1992, 175(2):377-385.
41. Hauswirth A.W., Natter S., Ghannadan M., Majlesi Y., Schernthaner G.H., Sperr W.R., et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002, 110(1):102-109.
42. Vrtala S., Mayer P., Ferreira F., Susani M., Sehon A.H., Kraft D., et al. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2. J Allergy Clin Immunol 1996, 98(5 Pt 1):913-921.
43. Valenta R., Kraft D. From allergen structure to new forms of allergen-specific immunotherapy. Curr Opin Immunol 2002, 14(6):718-727.
44. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002, 2(6):446-453.
45. Wurtzen P.A., Lund L., Lund G., Holm J., Millner A., Henmar H. Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity. Int Arch Allergy Immunol 2007, 144(4):287-295.
46. Henmar H., Lund G., Lund L., Petersen A., Wurtzen P.A. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol 2008, 153(3):316-323.
47. Vrtala S., Focke M., Kopec J., Verdino P., Hartl A., Sperr W.R., et al. Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity. J Immunol 2007, 179(3):1730-1739.
48. Bauer L., Bohle B., Jahn-Schmid B., Wiedermann U., Daser A., Renz H., et al. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol 1997, 107(3):536-541.
49. Godkin A.J., Smith K.J., Willis A., Tejada-Simon M.V., Zhang J., Elliott T., et al. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J Immunol 2001, 166(11):6720-6727.